Given the recent success of PD-1/PD-L1 inhibitors in clinical trials for metastatic melanoma, we used a well annotated cohort of metastatic melanoma samples to characterize PD-L1 expression and T cell content and the association with clinical outcome, using an automated, quantitative method. PD-L1 expressing tumors were more likely to have higher TILs. Both overall TIL content and the percent of CD8 positive cells were independent predictors of improved survival, and retained their independence on multivariable analysis. Patients with specimens lacking inflammation were more likely to develop early brain metastases. Moreover, the anatomic site of biopsy appears to be associated with variability in TIL content. Biomarker studies of patients treated with PD-1/PD-L1 inhibitors should include specimens from multiple sites, when possible, to determine whether these differences are clinically meaningful and whether assays combining PD-L1 expression and TIL characterization might be more predictive of response to therapy than PD-L1 alone. Furthermore, additional studies of anatomic sites with less PD-L1 expression and T cell infiltrate are needed to determine if discordant responses to PD-1/PD-L1 inhibitors are seen at those sites.
INTRODUCTION
Melanoma is considered an "immunogenic" tumor, responsive to immunologic manipulation. Cytokine therapies, including high dose interleukin-2 and interferon-α have been used to treat melanoma for decades, with responses in subsets of patients (1) (2) (3) . In recent years, immune checkpoint inhibitors, including monoclonal antibodies against CTLA-4, PD-1, PD-L1, LAG-3 and others have been studied. Antibodies that activate co-stimulatory molecules on T cells, such as GITR, CD-137, OX-40, CD-27 and CD-40 have entered clinical trials, as reviewed (4) (5) .
Ipilimumab, the first anti-CTLA-4 antibody was FDA approved in 2011 based on improvement in overall survival compared with a peptide vaccine (6) . Pembrolizumab was the first PD-1 inhibitor to be approved (7) (8) . Nivolumab, also a PD-1 inhibitor, was approved for patients with metastatic melanoma based on unprecedented activity (9) (10) , and additional inhibitors of PD-1 and PD-L1 are being evaluated in clinical trials. Notably, response rates to nivolumab and pembrolizumab are approximately 30%, significantly higher than older immune therapies, and responses can be durable.
Attempts have been made to identify predictors of response to PD-1/PD-L1 inhibitors.
The overall response rate in a phase I study of nivolumab was 41%, and in patients with available tissue for assessment of PD-L1 levels in tumor cells, there was a relationship between ligand expression and response. None of the PD-L1 negative tumors responded, while 36% of the PD-L1 expressing tumors responded (9) . Of note, not all patients had melanoma. A second phase I trial using nivolumab in solid tumors showed a similar result (11) . In the phase I study of pembrolizumab in patients with advanced melanoma, the percentage of patients with PD-L1 positive tumors was higher (71%), as reviewed (12) . The response rate among patients with PD- L1 positive or negative tumors was 49% and 13%, respectively, again indicating an association between PD-L1 positivity and response. When the threshold for positivity was raised to >10% of tumor cells, response rates in PD-L1 positive and negative group rose to 52% and 23%.
MPDL3280A is a monoclonal antibody to PD-L1; in a phase I trial of this drug in multiple tumor types, some association was found between treatment response and PD-L1 staining in the tumor microenvironment (but not in tumor cells) (13) .
A variety of staining reagents and antibodies were used in these studies, and variable cutpoints for positivity and negativity were employed; some studies used >1% tumor staining as a cutpoint for positivity, while others used >5%. Despite the variability, studies consistently show that although PD-L1 positive tumors are more likely to respond to therapy, not all do, while some of the patients without apparent tumor or tumor microenvironment expression of PD-L1 do respond. Additional factors therefore affect activity of this class of agents.
Taube et al. recently studied melanoma specimens from 110 patients (56 metastatic, 54 primary specimens) for presence of T cells and PD-L1 staining patterns (14) . They identified four patient groups; 41% had tumors that were both PD-L1 positive and had associated tumor infiltrating lymphocytes (TILs), 1% had PD-L1 positive tumors without TILs, 13% had TILs without PD-L1 positivity and 45% had neither. Tumor inflammation and the type of infitrating cells might affect response to therapy, as secretion of interferon-γ by T cells is known to induce PD-L1 tumor expression (15) . This interaction might potentiate activity of PD-1/PD-L1 inhibiting antibodies.
The location of a metastatic tumor might affect the inflammatory process. For example, Hamilton et al studied 26 matched brain and extra-cerebral metastases for gene expression profiling and found differences in pathways associated with T cell activity (16 Our purpose was to expand on the studies by Taube et al., and further characterize T cell infiltration in PD-L1 positive and negative metastatic melanoma specimens and to determine the association with clinical outcome using a larger cohort of metastatic melanoma specimens, well annotated for clinical outcome. Seeing that melanoma tends to metastasize to the brain frequently, we studied the assciation between PD-L1 positivity and/or T cell infiltrate and time to development of brain metastases. PD-L1 expression and T cell infiltrates were studied in metastatectomy specimens from a number of sites, including brain lesions. To obtain more accurate measures of PD-L1 expression and TILs, we employed a method of quantitative immunofluorescence and characterized TILs by CD-4 versus CD-8 expression, which has been used in a number of prior studies (17) (18) (19) .
MATERIAL AND METHODS

Cell lines and Western blotting
Early passage melanoma cell cultures and cell lines were grown in OptiMEM media (Invitrogen) supplemented with 10% heat-inactivated FBS (Invitrogen) and antibioticantimycotic (penicillin, streptomycin, amphotericin B; Invitrogen). Western blotting was performed by standard methods. β-Actin was utilized to determine sample loading.
Tissue microarray (TMA) construction
We constructed a TMA of metastatic melanoma samples using methods previously described (20) (21) (22) . This TMA has been previously described (23 inhibitors. Of the patients treated with immune therapy, 42% had sample acquisition after administration of immune therapy (one third received ipilimumab), 58% had sample acquisition before. Specimens included metastases from several sites: lymph nodes (26), skin (11), soft tissue (25) and visceral metastases (53 total, 40 cerebral and 13 extra-cerebral). In 17 cases more than one metastatic site was represented.
To verify antibody specificity, we used control TMAs containing placental and tonsil tissue (known to be positive for PD-L1) and pellets from MEL-624 cell lines, overexpressing or not overexpressing PD-L1, as previously described (14, 17) .
Immunofluorescence and Automated Quantitative Analysis (AQUA)
TMAs were heated for 30 minutes at 60˚C, deparaffinized and rehydrated through xylene and serial dilutions of ETOH and H 2 O. Slides were boiled at 100˚C for 10 minutes in antigen retrieval buffer (Tris-EDTA-pH9 buffer, DAKO) and incubated in peroxidase blocking reagent (K1500, DAKO) for 5 minutes. For PD-L1 staining, slides were incubated at room temperature for 15 min in ACE blocking buffer. To block endogenous biotin, slides were first incubated in Avidin blocking solution followed by Biotin blocking reagent (Vector Laboratories) for 15 minutes at 37˚C. Slides were incubated at 4°C overnight with anti-PD-L1 mouse monoclonal antibody (clone 5H1, generated by Dr. Lieping Chen) diluted at 1:400 in ACE block (24) .
Simultaneously, slides were incubated overnight with rabbit anti-S100 (1:100, cat#Z0311, DAKO) to localize cell membrane/cytoplasmic compartment and to create a tumor mask. As a negative control, a second TMA slide was incubated overnight in ACE block only. All TMAs (Molecular Probes, Inc.) was utilized. A nuclear mask was created by incubating the slides with 4,6-diamidine-2-phenylindole (DAPI) (Invitrogen, dilution 1:500).
Quantitative Determination of Target Expression
Details of image capturing and algorithms used for quantitative determination of target expression have been previously described (25) . PD-L1 signal on cells within the S100 tumor We further confirmed 5H1 antibody specificity by QIF ( Figure 1A ).
To characterize expression of PD-L1 and T cell infiltrates in metastatic melanoma, we utilized an array with 95 cases. Staining for PD-L1 was membranous and present in most cases within the tumor compartment, created by the S100 mask. Figure 1B shows an example of a PD-L1 positive case. In some cases PD-L1 was also expressed outside the tumor mask in the tumor microenvironment. Histospots were excluded if tissue was rendered insufficient (<3% of the histospot area) and if there was anomalous staining due to either abundant necrotic tissue or high background of the specimen on the negative control slide due to high endogenous biotin.
Using the Pearson correlation test we compared scores from the two cores for each specimen and found good intra-tumor reproducibility between matching cores for PD-L1 expression; R=0.87 (P<0.0001). Thus average AQUA scores were calculated for each case. 
Quantification of TIL and association with PD-L1 expression
Taube et al. previously showed that the majority of PD-L1 positive tumors also contained TILs (14) . To verify this, we used AQUA to quantify the degree of TIL as the percent area of CD3 expressing cells. Quantification was conducted by calculating the percent of TIL out of the total tumor area. We conducted further subset analysis by studying CD4, CD8 expressing TILs.
To assess heterogeneity within each case, we used linear regression and found a high degree of 
correlation between CD3 content in matching cores representing each tumor (R=0.78).
Correlation coefficients were somewhat lower for CD4 and CD8 subsets (R=0.52 for CD4 TILs, R=0.65 for CD8 TILs). Approximately half the metastatic melanomas demonstrated presence of intra-tumor immune infiltrates, consistent with findings of Taube et al. (14) . Given this reported distribution, we utilized the median value of CD3TIL area as a threshold for defining "high" TIL density versus "low" TIL density melanomas. The area of CD3 TILs ranged from 0%-89.96%
(mean-7.53%; median-1.94%). Most cases contained both CD4-and CD8-positive T-cell subsets and only a minority of cases were only CD8 positive; 70% of the high TIL cases (CD3 TIL area above the median) had both high CD4-and CD-8 TIL infiltration.
In the majority of cases, high PD-L1 expression was associated with high TIL densities as measured by the presence of CD3. High PD-L1 was similarly associated with infiltration of both CD4-and CD8 T-cell subsets. Associations measured by Chi-square analysis and by twosample t test utilizing continuous PD-L1 scores are shown in Table 1 and Supplementary Figure   S2 . An example of a TIL dense tumor spot demonstrating high CD3-, CD-4-and CD8 lymphocytic infiltrations and high PD-L1 expression is shown in Figure 1B .
Given the association between PD-L1 expression and TIL presence, we studied the association between tumor inflammation and overall survival. Utilizing the Cox proportional hazards method, high TIL densities were associated with improved OS. The association was statistically significant when analysing all TILs (by CD3 staining) and the CD8 subset, but not 
P=0
.04 for CD8 TILs; HR=0.87; CI (0.65-1.14), P=0.32 for CD4 TILs). To visualize the association between TIL density and survival, Kaplan-Meier curves were generated and P-values corresponding to these curves were obtained by the Mantel-Cox log-rank method; Figure 2 
PD-L1 expression and TIL infiltration in melanoma brain metastases compared to extracerebral metastases
Activity of PD-1/PD-L1 inhibitors is currently being studied in patients with untreated melanoma brain metastases but PD-L1 expression and lymphocytic infiltration have not been studied in cerebral metastases. We therefore analyzed 40 cerebral metastases included in our TMA. The distribution of AQUA scores for PD-L1 in these specimens ranged from 3.74 to 26.7 (mean-13.89). ANOVA of PD-L1 AQUA score distribution across different metastatic sites showed that brain and skin metastases had a trend towards lower PD-L1 expression compared to lymph node, soft tissue and other visceral sites, although differences did not reach statistical significance (P = 0.14, Figure 3A) . This difference was not significant by two-way comparison of dichotomized PD-L1 scores comparing cerebral to extra-cerebral sites (P=0.31, Table 2 ).
The percent area of CD3 positive TILs in brain metastatic specimens was 0-29.75%
(mean: 4.6%; median: 1.8%). Comparing across all sites of metastasis by ANOVA, locations with lowest PD-L1 expression (brain and skin metastases) also had the least infiltration of CD3-expressing lymphocytes. The same finding was demonstrated for CD4-and CD8-expressing subsets. The association was statistically significant for CD3 TILs (P=0.02) and trended towards significance for the CD8-expressing TILs (P=0.08) ( Figure 3B, D) . By chi-square (χ 2 ) analysis comparing high and low T-cell-dense cases, cerebral metastases were more likely to have low Tcell content than extra-cerebral metastases (P=0.01 for CD3TILs). The association trended toward significance for the CD4 subset, and was significant for the CD8 subset (P=0.09 and
P=0.01, respectively) (Table 2).
Patients in this cohort were closely followed with serial surveillance MRI of the brain.
We studied the association between brain metastasis free survival (BMFS), defined as the interval between diagnosis of metastatic disease and development of brain metastases, and PD- 
DISCUSSION
With the recent unprecedented success of PD-1/PD-L1 targeting antibodies for treating metastatic melanoma, our purpose was to further characterize PD-L1 expression in metastatic melanoma in the context of T cell infiltrates. High PD-L1 expression was associated with improved OS, but was not independent on multi-variable analysis, likely due to the association with T cell content. The percent area of T cells (using CD3 as a pan-T cell marker) was associated with improved OS on both uni-and multi-variable analysis, and infiltration of the CD8 subset was particularly associated with OS, whereas the CD4 subset was not. PD-L1 expression was lower in cerebral and skin metastases than other sites, and the corresponding T cell infiltration in brain and skin metastases was also less pronounced. High PD-L1 expression and T cell content in extra-cerebral tumors was associated with prolonged time to development of brain metastases.
Our studies confirm those by Taube et al, conducted on a smaller cohort of metastatic melanomas (56 cases) (14) . We studied 95 cases using a quantitative method to assess PD-L1 expression and T cell content. Using our automated method, we confirmed the association between PD-L1 expression and TIL content, and the association between high PD-L1 expression and improved survival. PD-L1 expression is up-regulated by T cell secretion of interferon-γ, and therefore patients with T cell dense tumors expressing PD-L1 are likely to have baseline improved immune surveillance (24) . In our cohort, the association appears to be independent of systemic immune therapy, although only three patients were treated with inhibitors of PD-1 or PD-L1. Based on preliminary observations among melanoma patients treated with these drugs, the association between PD-L1 expression and TIL content and overall survival is likely to be stronger now that PD-1 inhibitors have been approved for this population (26).
We conducted additional studies of subsets of T cells by analyzing CD4 and CD8 cell content. Both subsets were strongly associated with PD-L1 expression. However, only CD8 infiltrates were associated with improved OS. This is not surprising given the role of memory and effector CD8 cells in the inflammatory response to cytokine secretion and in preventing tumor invasion and metastasis (27) (28) . Our study was not designed to determine the regulatory versus helper CD4+ cell components, but the former likely explains the lack of association between CD4+ tumor content and improved survival (29) . However, our studies support those Published predictive correlative studies done on multi-institutional trials have focused primarily on PD-L1 expression. While this clearly correlates with T cell content (total and subsets), the prognostic value of CD3 TILs, in particular the CD8 subset, which is independent of PD-L1 expression, suggests that this should be included in predictive biomarker studies of patients treated with PD-1/PD-L1 inhibitors. This has been done in a small study of multiple tumor types (melanoma, renal cell carcinoma and lung cancer) treated with nivolumab at a single institution (31) . Tumor PD-L1 expression remained the strongest predictor of response to nivolumab, however, it is possible that a model incorporating both might best predict response to PD-1/PD-L1 inhibitors.
Research. 
Our TMA did not include analysis of multiple sites of metastases from individual patients, and did not allow for intra-patient comparison of PD-L1 expression and T cell content.
In previous studies in renal cell carcinoma, we showed that in a given patient, PD-L1 expression can vary at different anatomic sites (17) . Across all metastatic sites, PD-L1 expression appears to be somewhat lower in brain and skin metastases compared to other sites, although differences were not statistically significant, and the corresponding T cell infiltration analysis in brain and skin metastases indicated that metastases at these sites indeed have less T cell content. This is likely due to variability in factors associated with the tumor microenvironment. For example, higher PD-L1 tumor expression in lymph node metastases might be due to cytokine secretion by surrounding lymphocytes (32) . Some organs such as the lungs, have an abundance of dendritic cells and macrophages, cells that secrete interferon-γ (33) (34) . This might result in increases in tumor PD-L1 in these organs. tumor sample, when possible, metastatectomies should be studied rather than core needle or incisional biopsies.
Studies of the association between PD-L1 expression and response to PD-1/PD-L1 targeting drugs using variable cutpoints and reagents demonstrate that patients whose tumors express PD-L1 are more likely to respond to therapy (12) . Using a more quantitative method, we demonstrated variability in the degree of PD-L1 expression at different anatomic sites. We note that we were not able to study multiple sites of metastasis in individual patients, and with the data available to us at present, we cannot determine intra-patient variability in PD-L1 expression at different anatomic sites. Taube et al analyzed some patients with multiple specimens from different anatomic sites (31) . They noted some differences in PD-L1 staining and in T-cell infiltrate, but found that the highest scoring sample among multiple biopsies was the most likely to predict response to PD-L1 therapy. Inhibition of the PD-1/PD-L1 interaction at one site might result in increased TIL activity at that site and release of cytokines and circulating effector cells, which can result in anti-tumor T cell activity at distant sites which might be PD-L1 negative.
Alternatively, differences in PD-L1 expression and T-cell infiltrate at different anatomic sites might explain discordant responses seen in some patients, who might have shrinkage in one location and growth in another (7) (8) (9) (10) . The strong correlation between PD-L1 expression and T cell content within the tumor (as represented by the S100 tumor mask) further supports studies when possible, more than one metastatic site should be studied, with a particular focus on the site most requiring treatment, rather than previously resected tumor sites.
Brain metastases pose a particular challenge in the treatment of metastatic melanoma.
The incidence of cerebral dissemination in this disease is highest of all malignancies (36) .
Historically the prognosis has been poor, but with improved methods of local control of brain lesions, the prognosis is improving, and additional studies of this patient population are warranted. Our study shows increased time to brain metastases in PD-L1 positive tumors with high TIL content. However, the numbers in our study are small and validation in additional patient cohorts, particularly patients with paired brain and extra-cerebral samples, is warranted.
Moreover, our study is inherently limited by the fact that these metastatectomy samples were obtained at variable timepoints after diagnosis of metastatic disease, and inflammatory content might change with time and with therapy.
Ongoing studies of PD-1 inhibitors in patients with untreated brain metastases (such as NCT02085070) will enable us to determine whether brain lesions are biologically different in terms of T cell content and activity and whether brain metastases can be treated systemically with PD-1 inhibitors. The lower PD-L1 expression and TIL infiltrate in dermal metastases in our study provides some reassurance that the differences might not have therapeutic implications, as clinical experience indicates that dermal metastases are not less sensitive to this class of drugs.
Research. In summary, our studies confirm previous studies by Taube et al showing an association between PD-L1 expression and improved prognosis. These studies were conducted in a larger metastatic melanoma cohort using an automated, quantitative method. We further confirmed the association between PD-L1 expression and T cell infiltrate (by CD3 positivity), and characterized the T cell subtypes. Both overall TIL content and the percent of CD8 positive cells were independent predictors of improved survival, and retained their independence on multivariable analysis. High TIL content in extra-cerebral specimens was associated with increased time to developing brain metastases, suggesting that patients with higher TIL density tumors might be less likely to have tumor dissemination to the brain. Our study did not include multiple specimens from different anatomic sites in individual patients, but the anatomic site of biopsy appears to be associated with variability in PD-L1 expression and TIL content, with dermal and cerebral metastases having a lower TIL content and less PD-L1 expression.
Biomarker studies of patients treated with PD-1/PD-L1 inhibitors should include specimens from multiple sites, when possible, to determine whether these differences are clinically meaningful. The median PD-L1 intensity score in our cohort was utilized to dichotomize scores into low/high categories while the median CD3 TIL area was used as a threshold for defining high/low TIL density. High PD-L1 expression and high density of either CD3 positive TILs or the CD8 positive subset were significantly associated with longer overall survival. The median PD-L1 intensity score was utilized to dichotomize scores into low/high while the median CD3 TIL areas was used as thresholds for defining high/low TIL density. High density of CD3 positive TILs was significantly associated with a longer time to development of brain metastasis.
